Molecular Testing Improves Nodular Fasciitis Diagnosis - Scorecard - MDSpire

Molecular Testing Improves Nodular Fasciitis Diagnosis

  • By

  • Andrea Surnit

  • April 3, 2026

  • 3 min

Share

Clinical Scorecard: Molecular Testing Improves Nodular Fasciitis Diagnosis

At a Glance

CategoryDetail
ConditionNodular Fasciitis
Key MechanismsUSP6 rearrangements identified through molecular testing.
Target PopulationPatients with soft-tissue lesions suspected to be nodular fasciitis.
Care SettingPathology and diagnostic laboratories.

Key Highlights

  • Molecular testing identified USP6 rearrangements in all non-specific cases.
  • 66% of cases did not initially raise suspicion for nodular fasciitis.
  • Fluorescence in situ hybridization detected rearrangements in 83% of tested cases.
  • Next-generation sequencing resolved inconclusive cases with USP6 gene fusions.
  • Atypical fusions were found in younger patients compared to common fusions.

Guideline-Based Recommendations

Diagnosis

  • Utilize molecular testing for cases with inconclusive morphology or clinicopathological discordance.

Management

  • Confirm diagnosis through histopathology, immunohistochemistry, and molecular testing.

Monitoring & Follow-up

  • Monitor for symptoms and histologic features consistent with nodular fasciitis.

Risks

  • Misdiagnosis as more aggressive tumors due to non-specific presentations.

Patient & Prescribing Data

Mean age of 34 years, with no sex predominance.

Patients may present with pain or neurologic deficits rather than superficial masses.

Clinical Best Practices

  • Incorporate molecular diagnostics in the evaluation of soft-tissue lesions.
  • Recognize atypical presentations of nodular fasciitis to improve diagnostic confidence.

References

Original Source(s)

Related Content